← All trials
NCT05461339
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2022
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Jul 18, 2022
- Last posted
- Jul 19, 2022
- Enrollment
- 488
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TOT Biopharm Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Zhaoke (Guangzhou) Pharmaceutical LimitedCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.